Menu
2019

RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights

23 July, 2019

Key Highlights and Upcoming Milestones:

  • U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019

 

  • Preparations ongoing for the potential U.S. commercial launch of Talicia in Q4/2019, subject to FDA approval, with RedHill’s established sales force, led by the Company’s experienced commercial management team

 

  • FDA meetings planned to take place in H2/2019 to discuss the path to potential approval of RHB-104 for Crohn’s disease

 

  • Initiation of pivotal Phase 3 study activities with RHB-204 for first-line treatment of pulmonary nontuberculous mycobacteria (NTM) infections expected in Q4/2019

  • Debt-free balance sheet with $34.9 million cash balance as of June 30, 2019

TEL-AVIV, Israel and RALEIGH, N.C., July 23, 2019 RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today reported its financial results and operational highlights for the quarter ended June 30, 2019.

“We continue to maintain strong financial discipline while implementing our strategic commercial and development plans. We achieved a significant milestone with the FDA acceptance of the Talicia NDA for priority review earlier this month. With a PDUFA date of November 2, 2019, we continue our focus on preparations for the potential U.S. commercial launch of Talicia in the fourth quarter of this year, subject to FDA approval” said Micha Ben Chorin, RedHill’s Chief Financial Officer.

Financial highlights for the quarter ended June 30, 20191 

  • Net Revenues of $1.6 million in the second quarter of 2019, compared to $1.7 million in the first quarter of 2019.

  •  Gross Profit of $1.1 million in the second quarter of 2019, compared to $1.3 million in the first quarter of 2019.

  • Research and Development Expenses of $7.0 million in the second quarter of 2019, compared to $5.4 million in the first quarter of 2019. The increase is attributable primarily to the one-time PDUFA payment of $2.6 million for the Talicia NDA submission.

  • Selling, Marketing and Business Development Expenses of $4.1 million in the second quarter of 2019, compared to $3.1 million in the first quarter of 2019. The increase is attributable to the expansion of the commercial operations team with several key executive hires, as well as preparations for the potential commercial launch of Talicia in the U.S.

  • General and Administrative Expenses of $2.4 million in the second quarter of 2019, compared to $2.0 million in the first quarter of 2019. The increase is attributable primarily to preparations for the potential U.S. launch of Talicia.

  • Operating Loss of $12.4 million in the second quarter of 2019, compared to $9.2 million in the first quarter of 2019. The increase is primarily due to the PDUFA payment of $2.6 million and the increase in Selling, Marketing and Business Development Expenses, as described above.

  • Net Cash Used in Operating Activities of $10.4 million in the second quarter of 2019, compared to $7.5 million in the first quarter of 2019. The increase is attributable primarily to the one-time PDUFA fee of $2.6 million for the Talicia NDA submission.

  •  Cash Balance2 as of June 30, 2019 was $34.9 million, compared to $45.5 million as of March 31, 2019.


Operational Highlights:

Talicia (RHB-105)3 - H. pylori Infection
The U.S. Food and Drug Administration (FDA) has accepted for priority review the NDA for Talicia for H. pylori infection. The NDA for Talicia was assigned a target Prescription Drug User Act (PDUFA) action date of November 2, 2019. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation, in addition to patent protection extending until at least 2034. Assuming FDA approval, RedHill plans to launch Talicia in the U.S. in the fourth quarter of 2019 with the Company’s established sales force, led by RedHill’s highly experienced commercial management team. The Company further strengthened its commercial management team in the second quarter of 2019 including several key executive hires.

RHB-104 - Crohn’s Disease
FDA meetings are planned to take place in the second half of 2019 to discuss the development path toward potential approval of RHB-104, including the design of a confirmatory Phase 3 study. The MAP US randomized, double-blind, placebo-controlled first Phase 3 study with RHB-104 for Crohn’s disease successfully met both its primary endpoint and key secondary endpoints and presented the benefit of RHB-104, including as an add-on therapy to standard-of-care treatments for Crohn’s disease, such as anti-TNFs.

RHB-204 - Pulmonary Nontuberculous Mycobacteria (NTM) Infections        
RedHill plans to initiate pivotal Phase 3 study activities with RHB-204 for the treatment of pulmonary NTM infections in the fourth quarter of 2019, subject to completion of the ongoing supportive non-clinical program and additional input from the FDA. The study is intended to assess the efficacy and safety of RHB-204 and potentially support its approval as a stand-alone, first-line treatment for Mycobacterium avium complex (MAC) disease, the most common cause of pulmonary NTM infections4.

BEKINDA® (RHB-102) - Gastroenteritis & Gastritis and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
RedHill is currently working toward a confirmatory Phase 3 study to support a potential NDA for BEKINDA for acute gastroenteritis and gastritis. This study will follow the successful completion of a first Phase 3 study with BEKINDA for acute gastroenteritis and gastritis, as well as guidance provided by the FDA.

YELIVA® (opaganib, ABC294640) - Cholangiocarcinoma
The ongoing Phase 2a study evaluating the activity of orally-administered YELIVA in advanced cholangiocarcinoma (bile duct cancer) continues to enroll patients in the second stage of the two-stage study design. Enrollment of the full cohort of 39 evaluable patients is expected to be completed by the end of 2019.

Conference Call and Webcast Information:

The Company will host a conference call on Tuesday, July 23, 2019 at 8:30 a.m. EDT to review the second quarter 2019 financial results and operational highlights.

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: +1-866-966-1396; International: +1-631-510-7495; and Israel: +972-3-721-7998; The access code for the call is: 5754875.

The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events. Please access the Company's website at least 15 minutes ahead of the conference call to register.

 

About RedHill Biopharma Ltd.      
RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill commercializes and promotes several gastrointestinal products in the U.S.: Donnatal® - a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; EnteraGam® - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools and Mytesi® - an anti-diarrheal drug indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. RedHill’s key clinical late-stage development programs include: (i) Talicia® (RHB-105) for the treatment and eradication of Helicobacter pylori infection with a U.S. NDA submitted and accepted for priority review; (ii) RHB-104, with positive top-line results from a first Phase 3 study for Crohn's disease; (iii) RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (iv) BEKINDA® (RHB-102), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) YELIVA® (ABC294640), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; (vi) RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and (vii) RHB-107, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the approval of the NDA for Talicia® by the FDA and such approval’s timing, the initiation and timing of the commercial launch of Talicia®, the timing of meetings scheduled with the FDA, including in regards with RHB-104 for Crohn’s disease, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidates; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully commercialize and promote Donnatal®, EnteraGam® and Mytesi®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 26, 2019, as amended on May 15, 2019. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

 

 

Company contact:

Adi Frish

Senior VP Business Development & Licensing

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com

 

IR contact (U.S.):

Timothy McCarthy, CFA, MBA

Managing Director, Relationship Manager

LifeSci Advisors, LLC

+1-212-915-2564

tim@lifesciadvisors.com

 

 

REDHILL BIOPHARMA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

June 30, 

 

 

June 30, 

 

  

2019

    

2018

    

 

2019

    

2018

 

 

U.S. dollars in thousands

 

NET REVENUES

 

 1,563

 

 2,350

 

 

 3,300

 

 4,795

COST OF REVENUES

 

 425

 

 725

 

 

 842

 

 1,655

GROSS PROFIT

 

 1,138

 

 1,625

 

 

 2,458

 

 3,140

RESEARCH AND DEVELOPMENT EXPENSES, net

 

 6,972

 

 6,044

 

 

 12,344

 

 12,460

SELLING, MARKETING AND BUSINESS DEVELOPMENT EXPENSES

 

 4,147

 

 3,123

 

 

 7,283

 

 6,293

GENERAL AND ADMINISTRATIVE EXPENSES

 

 2,399

 

 2,015

 

 

 4,424

 

 3,939

OPERATING LOSS

 

 12,380

 

 9,557

 

 

 21,593

 

 19,552

FINANCIAL INCOME

 

 1,546

 

 156

 

 

 948

 

 239

FINANCIAL EXPENSES

 

 74

 

 1,717

 

 

 133

 

 1,740

FINANCIAL EXPENSES (INCOME), net

 

 (1,472)

 

 1,561

 

 

(815)

 

 1,501

LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD

 

 10,908

 

 11,118

 

 

 20,778

 

 21,053

 

 

 

 

 

 

 

 

 

 

LOSS PER ORDINARY SHARE, basic and diluted (U.S. dollars):

 

0.04

 

0.05

 

 

0.07

 

0.10

WEIGHTED AVERAGE OF ORDINARY SHARES (in thousands)

 

 283,687

 

 213,439

 

 

 283,687

 

 213,316

 

 

 

 

 

REDHILL BIOPHARMA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

 

 

 

June 30, 

 

December 31,

 

 

2019

 

2018

 

 

Unaudited

 

Audited

 

 

U.S. dollars in thousands

CURRENT ASSETS:

 

 

    

 

Cash and cash equivalents

 

 8,995

 

 29,005

Bank deposits

 

 9,403

 

 8,271

Financial assets at fair value through profit or loss

 

 16,471

 

 15,909

Trade receivables

 

 963

 

 958

Prepaid expenses and other receivables

 

 2,315

 

 1,876

Inventory

 

 1,826

 

 769

 

 

 39,973

 

 56,788

NON-CURRENT ASSETS:

 

 

 

 

Bank deposits

 

 147

 

 140

Fixed assets

 

 250

 

 163

Right-of-use assets

 

 4,005

 

 —

Intangible assets

 

 5,320

 

 5,320

 

 

 9,722

 

 5,623

TOTAL ASSETS

 

 49,695

 

 62,411

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES: 

 

 

 

 

Accounts payable

 

 4,743

 

 3,324

Lease liabilities

 

 845

 

 —

Accrued expenses and other current liabilities

 

 8,465

 

 7,057

 

 

 14,053

 

 10,381

 

 

 

 

 

NON-CURRENT LIABILITIES:

 

 

 

 

Derivative financial instruments

 

 13

 

 344

Lease liabilities

 

 3,225

 

 —

Royalty obligation

 

 500

 

 500

 

 

 3,738

 

 844

TOTAL LIABILITIES

 

 17,791

 

 11,225

 

 

 

 

 

 

 

 

 

 

EQUITY:

 

 

 

 

Ordinary shares

 

 767

 

 767

Additional paid-in capital

 

 219,505

 

 219,505

Accumulated deficit

 

 (188,368)

 

 (169,086)

TOTAL EQUITY

 

 31,904

 

 51,186

 

 

 

 

 

TOTAL LIABILITIES AND EQUITY

 

 49,695

 

 62,411

 

 

 

REDHILL BIOPHARMA LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30, 

 

June 30, 

 

  

2019

    

2018

 

2019

    

2018

 

 

U.S. dollars in thousands

OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Comprehensive loss

 

 (10,908)

 

 (11,118)

 

 (20,778)

 

 (21,053)

Adjustments in respect of income and expenses not involving cash flow:

 

 

 

 

 

 

 

 

Share-based compensation to employees and service providers

 

 937

 

 733

 

 1,496

 

 1,539

Depreciation

 

 226

 

 23

 

 456

 

 45

Fair value adjustments on derivative financial instruments

 

 (1,304)

 

 1,667

 

 (331)

 

 1,617

Fair value losses (gains) on financial assets at fair value through profit or loss

 

 (35)

 

 13

 

 (87)

 

 112

Revaluation of bank deposits

 

 (60)

 

 (13)

 

 (70)

 

 77

Exchange differences in respect of lease liabilities

 

 35

 

 —

 

 41

 

 —

Exchange differences in respect of cash and cash equivalents

 

 (23)

 

 53

 

 (39)

 

 67

 

 

 (224)

 

 2,476

 

 1,466

 

 3,457

Changes in assets and liability items:

 

 

 

 

 

 

 

 

Decrease (Increase) in trade receivables

 

 457

 

 13

 

 (5)

 

 (268)

Decrease (Increase) in prepaid expenses and other receivables

 

 (1,072)

 

 188

 

 (439)

 

 1,459

Increase in inventory

 

 (538)

 

 (130)

 

 (1,057)

 

 (37)

Increase (decrease) in accounts payable

 

 330

 

 1,299

 

 1,419

 

 (782)

Increase (decrease) in accrued expenses and other current liabilities

 

 1,502

 

 (1,127)

 

 1,408

 

 (671)

 

 

 679

 

 243

 

 1,326

 

 (299)

Net cash used in operating activities

 

 (10,453)

 

 (8,399)

 

 (17,986)

 

 (17,895)

INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchase of fixed assets

 

 (128)

 

 (2)

 

 (134)

 

 (15)

Change in investment in current bank deposits

 

 (3,200)

 

 5,000

 

 (1,069)

 

 4,869

Purchase of financial assets at fair value through profit or loss

 

 (1,942)

 

 (42)

 

 (2,575)

 

 (1,088)

Proceeds from sale of financial assets at fair value through profit or loss

 

 1,880

 

 1,500

 

 2,100

 

 3,450

Net cash provided by investing activities

 

 (3,390)

 

 6,456

 

 (1,678)

 

 7,216

FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Exercise of options into ordinary shares

 

 —

 

 —

 

 —

 

 355

Principal elements of lease payments

 

 (199)

 

 —

 

 (385)

 

 —

Repayment of payable in respect of intangible asset purchase

 

 —

 

 —

 

 —

 

 (500)

Net cash used in financing activities

 

 (199)

 

 —

 

 (385)

 

 (145)

DECREASE IN CASH AND CASH EQUIVALENTS

 

 (14,042)

 

 (1,943)

 

 (20,049)

 

 (10,824)

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

 

 23

 

 (53)

 

 39

 

 (67)

BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD

 

 23,014

 

 7,560

 

 29,005

 

 16,455

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD

 

 8,995

 

 5,564

 

 8,995

 

 5,564

SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH

 

 162

 

 148

 

 325

 

 415

SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Acquisition of right-of-use assets by means of lease liabilities

 

1,101

 

 —

 

 2,681

 

 —

 

 

1 All financial highlights are approximate and are rounded to the nearest hundreds of thousands.

2 Including cash and short-term investments (bank deposits and financial assets at fair value).

3 Talicia® (RHB-105), BEKINDA® (RHB-102) and YELIVA® (opaganib, ABC294640) are investigational new drugs, not available for commercial distribution.

4 Wassilew N et al. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration 91.5 (2016): 386-402.

Related Documents
Download file344.7 Kb